Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
NCT00703170
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Resistant Solid Malignancies
Interventions
DRUG:
Temsirolimus
DRUG:
Pegylated liposomal doxorubicin
Sponsor
Washington University School of Medicine